Theradex® has over 27 years of oncology clinical trials experience with an emphasis
on Phase I studies. Since our founding in 1982, we have monitored and held the data
for all US National Cancer Institute Phase I trials.
Theradex® has supported both broad and target Phase II programs for our clients.
From single center two-stage design to multinational randomized Phase II programs.
Theradex has the in-house expertise to support your research program.
Theradex® has successfully managed international Phase III programs supporting
the development of cytotoxics, biologics and molecular targeted therapies.